Have a feature idea you'd love to see implemented?
Let us know!
TGTX Tg Therapeutics Inc
Price (delayed)
$34.55
Market cap
$5.38B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.09
Enterprise value
$5.43B
TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active
Highlights
The equity is up by 17% year-on-year and by 8% since the previous quarter
The company's net income has shrunk by 115% QoQ but it rose by 45% YoY
Tg Therapeutics's EPS has shrunk by 113% QoQ but it has surged by 55% YoY
TGTX's debt has soared by 133% YoY and by 127% QoQ
The gross margin has decreased by 9% YoY and by 4.8% QoQ
Key stats
What are the main financial stats of TGTX
Market
Valuations
Earnings
Shares outstanding
155.67M
Market cap
$5.38B
Enterprise value
$5.43B
Price to book (P/B)
27.84
Price to sales (P/S)
18.93
EV/EBIT
962.91
EV/EBITDA
946.64
EV/Sales
20.52
Revenue
$264.79M
EBIT
$5.64M
EBITDA
$5.74M
Free cash flow
-$28.11M
Per share
Balance sheet
Liquidity
EPS
-$0.09
Free cash flow per share
-$0.19
Book value per share
$1.24
Revenue per share
$1.82
TBVPS
$4.04
Total assets
$586.01M
Total liabilities
$393.86M
Debt
$252.58M
Equity
$192.16M
Working capital
$448.96M
Debt to equity
1.31
Current ratio
4.59
Quick ratio
3.66
Net debt/EBITDA
9.66
Margins
Efficiency
Dividend
EBITDA margin
2.2%
Gross margin
88.3%
Net margin
-5.4%
Operating margin
-0.2%
Return on assets
-3.4%
Return on equity
-8.3%
Return on invested capital
1.6%
Return on capital employed
1.2%
Return on sales
2.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TGTX stock price
How has the Tg Therapeutics stock price performed over time
Intraday
10.91%
1 week
12.01%
1 month
41.77%
1 year
180.44%
YTD
102.28%
QTD
47.71%
Financial performance
How have Tg Therapeutics's revenue and profit performed over time
Revenue
$264.79M
Gross profit
$233.85M
Operating income
-$505,000
Net income
-$14.36M
Gross margin
88.3%
Net margin
-5.4%
TGTX's net margin has shrunk by 120% QoQ but it has soared by 61% YoY
The company's net income has shrunk by 115% QoQ but it rose by 45% YoY
Tg Therapeutics's operating margin has shrunk by 101% QoQ but it has surged by 98% YoY
The operating income has plunged by 100% from the previous quarter but it has soared by 97% YoY
Growth
What is Tg Therapeutics's growth rate over time
Valuation
What is Tg Therapeutics stock price valuation
P/E
N/A
P/B
27.84
P/S
18.93
EV/EBIT
962.91
EV/EBITDA
946.64
EV/Sales
20.52
Tg Therapeutics's EPS has shrunk by 113% QoQ but it has surged by 55% YoY
The P/B is 71% above the last 4 quarters average of 16.3 and 24% above the 5-year quarterly average of 22.4
The equity is up by 17% year-on-year and by 8% since the previous quarter
The P/S is 100% below the 5-year quarterly average of 5002.7 but 97% above the last 4 quarters average of 9.6
The revenue rose by 40% YoY but it fell by 24% QoQ
Efficiency
How efficient is Tg Therapeutics business performance
Tg Therapeutics's return on sales has surged by 131% YoY but it has shrunk by 93% QoQ
TGTX's ROIC has soared by 121% YoY but it has shrunk by 96% QoQ
The company's return on equity has shrunk by 114% QoQ but it has surged by 77% YoY
The ROA has plunged by 113% from the previous quarter but it has soared by 69% YoY
Dividends
What is TGTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TGTX.
Financial health
How did Tg Therapeutics financials performed over time
The total assets is 49% higher than the total liabilities
Tg Therapeutics's total liabilities has surged by 137% YoY and by 76% QoQ
The total assets has soared by 77% YoY and by 46% QoQ
TGTX's debt is 31% higher than its equity
TGTX's debt has soared by 133% YoY and by 127% QoQ
The debt to equity has soared by 108% from the previous quarter and by 98% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.